Argent Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.6M Sell
11,495
-41
-0.4% -$5.74K 0.44% 60
2025
Q4
$1.42M Sell
11,536
-86
-0.7% -$10.5K 0.4% 63
2025
Q3
$1.29M Buy
11,622
+798
+7% +$90.7K 0.38% 71
2025
Q2
$1.2M Buy
10,824
+399
+4% +$42.5K 0.37% 74
2025
Q1
$1.17M Sell
10,425
-920
-8% -$94.9K 0.39% 69
2024
Q4
$1.05M Buy
11,345
+142
+1% +$12.8K 0.39% 76
2024
Q3
$939K Sell
11,203
-83
-0.7% -$6.33K 0.35% 80
2024
Q2
$774K Buy
11,286
+533
+5% +$35.6K 0.31% 81
2024
Q1
$788K Sell
10,753
-301
-3% -$23.1K 0.31% 80
2023
Q4
$895K Sell
11,054
-169
-2% -$13.2K 0.39% 66
2023
Q3
$841K Buy
11,223
+29
+0.3% +$2.23K 0.38% 66
2023
Q2
$863K Buy
11,194
+299
+3% +$23.8K 0.4% 68
2023
Q1
$904K Sell
10,895
-476
-4% -$39.4K 0.43% 61
2022
Q4
$976K Sell
11,371
-53
-0.5% -$4.2K 0.51% 54
2022
Q3
$705K Buy
11,424
+391
+4% +$24.7K 0.41% 63
2022
Q2
$682K Buy
11,033
+1,178
+12% +$72.9K 0.38% 71
2022
Q1
$580K Buy
+9,855
New +$630K 0.31% 84
2020
Q1
Sell
-1,380
Closed -$88K 266
2019
Q4
$88K Buy
+1,380
New +$89.9K 0.07% 162

Other funds holding GILD

Argent Advisors's GILD Position: Q1 2026 in Review

Argent Advisors reduced its Gilead Sciences (GILD) stake by 0.36% in Q1 2026, selling an estimated $5.74K and leaving 11,495 shares worth $1.6M. The position accounts for 0.44% of the portfolio, ranked #60.

Argent Advisors first reported a position in GILD in Q4 2019 and has held it in 18 quarters since. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Argent Advisors held 11,495 shares of Gilead Sciences worth $1.6M as of Q1 2026.
  • Argent Advisors sold 41 Gilead Sciences shares in Q1 2026, an estimated $5.74K.
  • Gilead Sciences made up 0.44% of Argent Advisors's portfolio in Q1 2026, its #60 holding.
  • Argent Advisors first reported a position in Gilead Sciences in Q4 2019 and has held it in 18 quarters since.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Argent Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.